Growth hormone status during long-term hexarelin therapy
Rahim A, O'Neill PA, Shalet SM
Journal of Clinical Endocrinology & Metabolism (1998) · n=12
Sixteen weeks of twice-daily subcutaneous hexarelin in elderly subjects: mean GH AUC fell from 19.1 µg/L/h at baseline to 13.1 at week 1, 12.3 at week 4, and 10.5 at week 16 — a roughly 45% loss of the GH response, reversible after four weeks of washout. The receptor-desensitisation paper that grounds modern hexarelin cycling logic.
This is the long-term hexarelin therapy paper from Aftab Rahim, Peter A. O'Neill, and Stephen M. Shalet at the Christie Hospital (Manchester) and Hope Hospital (Salford), published in the Journal of Clinical Endocrinology and Metabolism in 1998. The paper is the source of the receptor-tachyphylaxis finding that grounds every modern practitioner-protocol cycling logic around hexarelin and that contributed materially to the eventual shift in practitioner stacks away from hexarelin toward selective secretagogues like Ipamorelin.
The design enrolled 12 healthy elderly subjects in a 16-week open protocol of twice-daily subcutaneous hexarelin at 1.5 µg/kg body weight. Acute GH response curves to a provocative test dose were measured at baseline (week 0) and after 1, 4, and 16 weeks of continued dosing, and again after a four-week washout. The headline pharmacodynamic finding is the progressive attenuation of the GH response over the dosing window: mean area-under-the-curve for GH fell from 19.1 µg/L/h at baseline to 13.1 at week 1 (the largest single drop, occurring within the first week of dosing), to 12.3 at week 4, to 10.5 at week 16 — approximately a 45% loss of the original GH-releasing capacity across the 16-week dosing arm (overall change-from-baseline p = 0.0003, with weeks 4 and 16 individually significant versus baseline). Insulin-like growth factor 1, IGFBP-3, body composition, and bone mineral density showed minimal change across the observation window despite the sustained dosing — the divergence between the acute GH-pulse response (which clearly desensitised) and the downstream hepatic IGF-1 axis and tissue-level endpoints (which did not move) is one of the structurally important findings of the paper. Critically, four weeks of washout substantially restored the GH response toward baseline, demonstrating that the tachyphylaxis is partial and reversible rather than permanent.
The mechanistic explanation is the standard ghrelin-receptor desensitisation sequence — β-arrestin recruitment to activated GHSR-1a, receptor internalisation, and somatotroph desensitisation — and is reviewed in detail in Mao, Tokudome, and Kishimoto 2014 and in the broader receptor-pharmacology literature for the ghrelin receptor class. The practical implication that the hexarelin peptide page treats as load-bearing is straightforward: any continuous-dosing hexarelin schedule is self-limiting at the receptor level, the maximum sustained GH response is roughly half the acute first-dose response, and four weeks of washout is sufficient to recover. Modern practitioner protocols that overlay short-cycle or pulsed-dosing logic on hexarelin trace directly to this paper.
The sample is small (n=12), the population is elderly healthy volunteers, and the protocol is open-label rather than placebo-controlled — appropriate for the receptor-tachyphylaxis pharmacodynamic question the paper addresses but limiting for any clinical-outcome inference. The dose (1.5 µg/kg twice daily subcutaneous) sits in the practitioner-relevant range but the desensitisation curve has not been independently characterised at higher or lower doses, at different frequencies, or in younger and non-elderly populations. The 16-week observation window is the longest published continuous-dosing characterisation but is short relative to the chronic dosing schedules of practitioner protocols, and the downstream IGF-1 and tissue endpoints that did not move within 16 weeks have not been characterised beyond that window. The receptor-desensitisation finding is mechanism-level evidence and does not address whether the residual GH pulse at week 16 is sufficient to drive whatever tissue endpoint the protocol is designed for — body composition, recovery, or other practitioner-protocol targets. The Christie/Hope Hospital group did not subsequently publish a follow-up study with the design that would settle that question. The paper's central evidentiary value is the desensitisation curve and the reversibility demonstration; treat downstream outcome inference cautiously. The /peptides/hexarelin page treats this paper as the mechanistic anchor for the cycle-design discussion and the GH-secretagogue discontinuation playbook extends the cycling logic across the class.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.